129 related articles for article (PubMed ID: 31800100)
1. Oral Squamous Cell Carcinoma as a Complication of Treatment for Recurrent High-Grade Serous Cancer.
Moses LE; Rotsides JM; Balogun FO; Persky MS; Muggia FM; Persky MJ
Laryngoscope; 2020 Nov; 130(11):2607-2610. PubMed ID: 31800100
[TBL] [Abstract][Full Text] [Related]
2. Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer?
Cannon TL; Lai DW; Hirsch D; Delacure M; Downey A; Kerr AR; Bannan M; Andreopoulou E; Safra T; Muggia F
Oncologist; 2012; 17(12):1541-6. PubMed ID: 22622148
[TBL] [Abstract][Full Text] [Related]
3. Oral squamous cell carcinoma in a patient treated with long-term pegylated liposomal doxorubicin for recurrent ovarian cancer.
Pezzoli M; Bona Galvagno M; Bongioannini G
BMJ Case Rep; 2015 Jan; 2015():. PubMed ID: 25589526
[TBL] [Abstract][Full Text] [Related]
4. Squamous cell carcinoma of the oral cavity in a woman with a 9-year history of ovarian cancer: is exposure to pegylated liposomal Doxorubicin a factor?
Randon G; Nicoletto MO; Milite N; Muggia F; Conte P
Oncologist; 2014 Apr; 19(4):429. PubMed ID: 24668330
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer.
Chambers LM; Pendlebury A; Rose PG; Yao M; DeBernardo R
Gynecol Oncol; 2020 Aug; 158(2):309-315. PubMed ID: 32499072
[TBL] [Abstract][Full Text] [Related]
6. Oral leukoplakia, a precancerous lesion of squamous cell carcinoma, in patients with long-term pegylated liposomal doxorubicin treatment.
Nomura H; Sakamoto K; Sugihara T; Okamoto S; Aoki Y; Tanigawa T; Matoda M; Omatsu K; Kanao H; Kato K; Utsugi K; Sugiyama Y; Takeshima N
Medicine (Baltimore); 2018 Feb; 97(7):e9932. PubMed ID: 29443777
[TBL] [Abstract][Full Text] [Related]
7. Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg/m2 in recurrent ovarian cancer.
Pendlebury A; DeBernardo R; Rose PG
Anticancer Drugs; 2017 Aug; 28(7):815-817. PubMed ID: 28542037
[TBL] [Abstract][Full Text] [Related]
8. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
[TBL] [Abstract][Full Text] [Related]
9. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study.
Blake EA; Bradley CA; Mostofizadeh S; Muggia FM; Garcia AA; Roman LD; Matsuo K
Arch Gynecol Obstet; 2019 Jun; 299(6):1641-1649. PubMed ID: 30824986
[TBL] [Abstract][Full Text] [Related]
11. Skin-mucous membrane disorder and therapeutic effect of pegylated liposomal doxorubicin in recurrent ovarian cancer.
Yamada Y; Kawaguchi R; Ito F; Iwai K; Niiro E; Shigetomi H; Tanase Y; Kobayashi H
J Obstet Gynaecol Res; 2017 Jul; 43(7):1194-1199. PubMed ID: 28544386
[TBL] [Abstract][Full Text] [Related]
12. Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand-foot syndrome: a newly recognized toxicity.
Pease DF; Peterson BA; Gilles S; Hordinsky MK; Bohjanen KA; Skubitz KM
Cancer Chemother Pharmacol; 2019 Jul; 84(1):217-221. PubMed ID: 31041511
[TBL] [Abstract][Full Text] [Related]
13. Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma.
Collins Y; Lele S
J Natl Med Assoc; 2005 Oct; 97(10):1414-6. PubMed ID: 16353663
[TBL] [Abstract][Full Text] [Related]
14. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
[TBL] [Abstract][Full Text] [Related]
15. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
[TBL] [Abstract][Full Text] [Related]
16. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
[TBL] [Abstract][Full Text] [Related]
17. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S; Nanayakkara N; Melara R; Bass MB; Litten J; Adewoye H; Wenham RM
Gynecol Oncol; 2014 Oct; 135(1):25-33. PubMed ID: 25019569
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
Pothuri B; Brodsky AL; Sparano JA; Blank SV; Kim M; Hershman DL; Tiersten A; Kiesel BF; Beumer JH; Liebes L; Muggia F
Cancer Chemother Pharmacol; 2020 Apr; 85(4):741-751. PubMed ID: 32055930
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Pegylated Liposomal Doxorubicin in Low-Grade Serous Ovarian Carcinoma.
Rose PG; Radeva M; Michener CM; Link N; Adbul-Karim F
Int J Gynecol Cancer; 2017 Jun; 27(5):907-911. PubMed ID: 28498259
[TBL] [Abstract][Full Text] [Related]
20. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
